# US 2001/0022976 A1 · Immunosuppressive and tumour-suppressive bone marrow factor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0022976 A1
- Document ID: US20010022976A1
- Status: Published application
- Kind: A1
- Application number: 09/819,178
- Filed: 2001-03-27
- Published: 2001-09-20
- Earliest claimed: 1995-02-03
- Assignees: London Health Sciences Centre
- Inventors: Sharwan K. Singhal
- Web page: https://patentgrep.com/patent/US20010022976A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- C12N 1/00: Microorganisms; Compositions thereof (medicinal preparations containing material from protozoa, bacteria or viruses A61K35/66, from algae A61K36/02, from fungi A61K36/06; preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines, A61K39/00); Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12P 1/00: Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12R 2001/91: Cell lines {; Processes using cell lines}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

A novel immunosuppressive factor derived from mammalian bone marrow factor is described, which inhibits T lymphocyte activation and TNF-α production by activated macrophages and also inhibits tumor and leukemia cell growth. The factor provides a novel therapeutic composition for treatment of tumors and of disorders associated with inflammatory reactions or T lymphocyte activation.

## Claims

### Claim 1

A purified, water soluble immunosuppressive factor characterised by a molecular weight less than 1000 daltons and movement as a single peak on reverse phase high performance liquid chromatography.

### Claim 2 (depends on 1)

The factor of claim 1 having the following biological activities:
(a) prevention or reduction of IL-2 production by activated T lymphocytes;
(b) prevention or reduction of TNF-α production by activated macrophages;
(c) prevention or reduction of proliferation of activated T lymphocytes; and
(d) inhibition of mixed lymphocyte reaction.

### Claim 3 (depends on 2)

The factor of claim 2 having the following further biological activity:
(a) inhibition of tumour growth in a mammal.

### Claim 4 (depends on 3)

The factor of claim 3 having the following further biological activity:
(a) inhibition of leukemia cell proliferation.

### Claim 5 (depends on 4)

The factor of claim 4 having the following further biological activity:
(a) inhibition of a graft versus host reaction in a mammal.

### Claim 6 (depends on 2)

The factor of claim 2 wherein the factor is derived from mammalian bone marrow cells.

### Claim 7 (depends on 6)

The factor of claim 6 wherein the bone marrow cells are myeloid progenitor cells.

### Claim 8 (depends on 1)

The factor of claim 1 having a molecular weight of less than 1000 daltons.

### Claim 9 (depends on 8)

The factor of claim 8 having a molecular weight of about 625 daltons.

### Claim 10 (depends on 1)

A method for inhibiting T lymphocyte activation in a mammal comprising administering to the mammal an effective amount of the factor of claim 1.

### Claim 11 (depends on 1)

A pharmaceutical composition for inhibiting T lymphocyte activation in a mammal comprising an effective amount of the factor of claim 1 and a pharmaceutically acceptable carrier

### Claim 12 (depends on 1)

Use of a composition comprising an effective amount of the factor of claim 1 and a pharmaceutically acceptable carrier to inhibit T lymphocyte activation in a mammal

### Claim 13 (depends on 1)

A method for treating or preventing a disorder associated with undesirable or excessive T lymphocyte activation, in a mammal, comprising administering to the mammal an effective amount of the factor of claim 1

### Claim 14 (depends on 13)

The method of claim 13 wherein the disorder is an autoimmune disease.

### Claim 15 (depends on 1)

The method of claim 1 wherein the autoimmune disease is rheumatoid arthritis, lupus erythematosus, multiple sclerosis or type I diabetes

### Claim 16 (depends on 13)

The method of claim 13 wherein the disorder involves allogeneic T lymphocyte interactions.

### Claim 17 (depends on 16)

The method of claim 16 wherein the disorder is graft versus host disease.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A pharmaceutical composition for treating or preventing a disorder associated with undesirable or excessive T lymphocyte activation comprising an effective amount of the factor of any of claims 1 to 9 and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

Use of a composition comprising an effective amount of the factor of any of claims 1 to 9 and a pharmaceutically acceptable carrier to treat or prevent a disorder associated with undesirable or excessive T lymphocyte activation.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method for inhibiting TNF-α production in a mammal comprising administering to the mammal an effective amount of the factor of any of claims 1 to 9.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A pharmaceutical composition for inhibiting TNF-α production in a mammal coming an effective amount of the factor of any of claims 1 to 9 and a pharmaceutically acceptable carrier.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

Use of a composition comprising an effective amount of the factor of any of claims 1 to 9 and a pharmaceutically acceptable carrier to inhibit TNF-α production in a mammal.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method for treating or preventing a disorder associated with undesirable or excessive TNF-α production, in a mammal, comprising administering to the mammal an effective amount of the factor of any of claims 1 to 9.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method for inhibiting growth of a tumour in a mammal comprising administering to the mammal an effective amount of the factor of any of claims 1 to 9.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A pharmaceutical composition for inhibiting growth of a tumour in a mammal comprising an effective amount of the factor of any of claims 1 to 9 and a pharmaceutically acceptable carrier.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

Use of a composition comprising an effective amount of the factor of any of claims 1 to 9 and a pharmaceutically acceptable carrier to inhibit growth of a tumour in a mammal.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method for inhibiting growth of a leukemia in a mammal comprising administering to the mammal an effective amount of the factor of any of claims 1 to 9.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A pharmaceutical composition for inhibiting growth of a leukemia in a mammal comprising an effective amount of the factor of any of claims 1 to 9 and a pharmaceutically acceptable carrier.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

Use of a composition comprising an effective amount of the factor of any of claims 1 to 9 and a pharmaceutically acceptable carrier to inhibit growth of a leukemia in a mammal.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method for preventing or treating, in a mammal, a disorder characterised by an abnormality in a signalling pathway, wherein the signalling pathway involves CD45 phosphatase activity, the method comprising administering to the mammal a therapeutically effective amount of the factor of any of claims 1 to 9.

### Claim 31

A method for preparing a purified immunosuppressive factor comprising the steps of
(a) culturing mammalian bone marrow cells to produce a factor-containing supernatant;
(b) subjecting the supernatant to solid phase extraction to produce a product;
(c) subjecting the product from step (b) to gel filtration to produce a product;
(d) subjecting the product from step (c) to anion exchange fast phase liquid chromatography to produce a product;
(e) subjecting the product from step (d) to amino-high performance liquid chromatography to produce a product; and
(f) subjecting the product from step (e) to reverse phase high performance liquid chromatography to product purified immunosuppressive factor.

### Claim 32 (depends on 31)

A purified immunosuppressive factor prepared in accordance with the method of claim 31.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A method for inhibiting IL-2 production by activated T lymphocytes in a mammal comprising administering to the mammal an effective amount of the factor of any of claims 1 to 9.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

A pharmaceutical composition for inhibiting IL-2 production by activated T lymphocytes in a mammal comprising an effective amount of the factor of any of claims 1 to 9 and a pharmaceutically acceptable carrier.
